Browse GTF2F2

Summary
SymbolGTF2F2
Namegeneral transcription factor IIF, polypeptide 2, 30kDa
Aliases RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location13q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF02270 Transcription initiation factor IIF
Function

TFIIF is a general transcription initiation factor that binds to RNA polymerase II and helps to recruit it to the initiation complex in collaboration with TFIIB. It promotes transcription elongation. This subunit shows ATP-dependent DNA-helicase activity.

> Gene Ontology
 
Biological Process GO:0000375 RNA splicing, via transesterification reactions
GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
GO:0000398 mRNA splicing, via spliceosome
GO:0006352 DNA-templated transcription, initiation
GO:0006354 DNA-templated transcription, elongation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0006370 7-methylguanosine mRNA capping
GO:0006397 mRNA processing
GO:0008380 RNA splicing
GO:0008543 fibroblast growth factor receptor signaling pathway
GO:0009301 snRNA transcription
GO:0009452 7-methylguanosine RNA capping
GO:0016073 snRNA metabolic process
GO:0019058 viral life cycle
GO:0019080 viral gene expression
GO:0019083 viral transcription
GO:0031334 positive regulation of protein complex assembly
GO:0032784 regulation of DNA-templated transcription, elongation
GO:0032786 positive regulation of DNA-templated transcription, elongation
GO:0032968 positive regulation of transcription elongation from RNA polymerase II promoter
GO:0034243 regulation of transcription elongation from RNA polymerase II promoter
GO:0036260 RNA capping
GO:0042795 snRNA transcription from RNA polymerase II promoter
GO:0043254 regulation of protein complex assembly
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044033 multi-organism metabolic process
GO:0044089 positive regulation of cellular component biogenesis
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0046782 regulation of viral transcription
GO:0048524 positive regulation of viral process
GO:0050434 positive regulation of viral transcription
GO:0050792 regulation of viral process
GO:0060260 regulation of transcription initiation from RNA polymerase II promoter
GO:0060261 positive regulation of transcription initiation from RNA polymerase II promoter
GO:0071774 response to fibroblast growth factor
GO:0098781 ncRNA transcription
GO:1903900 regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
GO:2000142 regulation of DNA-templated transcription, initiation
GO:2000144 positive regulation of DNA-templated transcription, initiation
Molecular Function GO:0000990 transcription factor activity, core RNA polymerase binding
GO:0000991 transcription factor activity, core RNA polymerase II binding
GO:0004386 helicase activity
Cellular Component GO:0000428 DNA-directed RNA polymerase complex
GO:0005667 transcription factor complex
GO:0005674 transcription factor TFIIF complex
GO:0016591 DNA-directed RNA polymerase II, holoenzyme
GO:0030880 RNA polymerase complex
GO:0044798 nuclear transcription factor complex
GO:0055029 nuclear DNA-directed RNA polymerase complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0090575 RNA polymerase II transcription factor complex
> KEGG and Reactome Pathway
 
KEGG hsa03022 Basal transcription factors
Reactome R-HSA-167242: Abortive elongation of HIV-1 transcript in the absence of Tat
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-112387: Elongation arrest and recovery
R-HSA-6803529: FGFR2 alternative splicing
R-HSA-1839126: FGFR2 mutant receptor activation
R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat
R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat
R-HSA-112382: Formation of RNA Pol II elongation complex
R-HSA-113418: Formation of the Early Elongation Complex
R-HSA-167158: Formation of the HIV-1 Early Elongation Complex
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167169: HIV Transcription Elongation
R-HSA-167161: HIV Transcription Initiation
R-HSA-167287: HIV elongation arrest and recovery
R-HSA-5663205: Infectious disease
R-HSA-168254: Influenza Infection
R-HSA-168255: Influenza Life Cycle
R-HSA-168273: Influenza Viral RNA Transcription and Replication
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-167290: Pausing and recovery of HIV elongation
R-HSA-167238: Pausing and recovery of Tat-mediated HIV elongation
R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA
R-HSA-77075: RNA Pol II CTD phosphorylation and interaction with CE
R-HSA-167160: RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
R-HSA-167162: RNA Polymerase II HIV Promoter Escape
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73776: RNA Polymerase II Promoter Escape
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75955: RNA Polymerase II Transcription Elongation
R-HSA-75953: RNA Polymerase II Transcription Initiation
R-HSA-76042: RNA Polymerase II Transcription Initiation And Promoter Clearance
R-HSA-73779: RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
R-HSA-6807505: RNA polymerase II transcribes snRNA genes
R-HSA-162582: Signal Transduction
R-HSA-190236: Signaling by FGFR
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5654738: Signaling by FGFR2
R-HSA-8851708: Signaling by FGFR2 IIIa TM
R-HSA-5655253: Signaling by FGFR2 in disease
R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes
R-HSA-167243: Tat-mediated HIV elongation arrest and recovery
R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript
R-HSA-167172: Transcription of the HIV genome
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-168325: Viral Messenger RNA Synthesis
R-HSA-72086: mRNA Capping
R-HSA-72172: mRNA Splicing
R-HSA-72163: mRNA Splicing - Major Pathway
R-HSA-72165: mRNA Splicing - Minor Pathway
Summary
SymbolGTF2F2
Namegeneral transcription factor IIF, polypeptide 2, 30kDa
Aliases RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location13q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GTF2F2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolGTF2F2
Namegeneral transcription factor IIF, polypeptide 2, 30kDa
Aliases RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location13q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GTF2F2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGTF2F2
Namegeneral transcription factor IIF, polypeptide 2, 30kDa
Aliases RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location13q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GTF2F2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6760.031
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.860.722
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5420.76
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.080.727
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1020.942
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0540.976
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1160.749
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4150.794
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2370.891
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0630.963
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4840.808
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0810.21
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GTF2F2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGTF2F2
Namegeneral transcription factor IIF, polypeptide 2, 30kDa
Aliases RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location13q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GTF2F2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGTF2F2
Namegeneral transcription factor IIF, polypeptide 2, 30kDa
Aliases RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location13q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GTF2F2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GTF2F2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGTF2F2
Namegeneral transcription factor IIF, polypeptide 2, 30kDa
Aliases RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location13q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GTF2F2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGTF2F2
Namegeneral transcription factor IIF, polypeptide 2, 30kDa
Aliases RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location13q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GTF2F2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGTF2F2
Namegeneral transcription factor IIF, polypeptide 2, 30kDa
Aliases RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location13q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GTF2F2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGTF2F2
Namegeneral transcription factor IIF, polypeptide 2, 30kDa
Aliases RAP30; TF2F2; ATP-dependent helicase GTF2F2; TFIIF-beta; general transcription factor IIF 30 kDa subunit; tr ......
Chromosomal Location13q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GTF2F2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.